Pascal Claudepierre

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 29

Top Topics

Health Insurance

Top Venues

The Journal of rheumatology

The British journal of dermatology

This page only lists publications with an associated author ORCID identifier.

Publications

Anna Moltó, Chris Serrand, Sandrine Alonso, Francis Berenbaum, Pascal Claudepierre, Bernard G Combe, Laure Gossec, Adeline Ruyssen-Witrand, Alain Saraux, Daniel Wendling, Thierry Lequerre, Maxime Dougados
Diagnosis challenges in inception cohorts in axial spondyloarthritis: the case of the French national DESIR cohort. RMD open 10 (3) (2024)
Léa Bastard, Pascal Claudepierre, Laetitia Penso, Emilie Sbidian, Laura Pina Vegas
Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (SNDS). RMD open 10 (1) (2024)
Léa Bastard, Pascal Claudepierre, Laetitia Penso, Emilie Sbidian, Laura Pina Vegas
Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (SNDS). RMD open 10 (1) (2024)
Maxime Dougados, Audrey Lardy-Cléaud, Emilie Desfleurs, Pascal Claudepierre, Philippe Goupille, Adeline Ruyssen-Witrand, Alain Saraux, Anne Tournadre, Daniel Wendling, Cédric Lukas
Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study. RMD open 10 (1) (2024)
Maxime Dougados, Audrey Lardy-Cléaud, Emilie Desfleurs, Pascal Claudepierre, Philippe Goupille, Adeline Ruyssen-Witrand, Alain Saraux, Anne Tournadre, Daniel Wendling, Cédric Lukas
Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study. RMD open 10 (1) (2024)
Léa Bastard, Pascal Claudepierre, Laetitia Penso, Emilie Sbidian, Laura Pina Vegas
Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (SNDS). RMD open 10 (1) (2024)
Laura Pina Vegas, Siham Iggui, Emilie Sbidian, Pascal Claudepierre
Impact of initiation of targeted therapy on the use of psoriatic arthritis-related treatments and healthcare consumption: a cohort study of 9793 patients from the French health insurance database (SNDS). RMD open 10 (3) (2024)
Anna Moltó, Chris Serrand, Sandrine Alonso, Francis Berenbaum, Pascal Claudepierre, Bernard G Combe, Laure Gossec, Adeline Ruyssen-Witrand, Alain Saraux, Daniel Wendling, Thierry Lequerre, Maxime Dougados
Diagnosis challenges in inception cohorts in axial spondyloarthritis: the case of the French national DESIR cohort. RMD open 10 (3) (2024)
Walter P Maksymowych, Pascal Claudepierre, Manouk de Hooge, Robert G W Lambert, Robert Landewé, Anna Molto, Désirée van der Heijde, Jack F Bukowski, Heather Jones, Ron Pedersen, Annette Szumski, Bonnie Vlahos, Maxime Dougados
Erosions on T1-Weighted Magnetic Resonance Imaging Versus Radiography of Sacroiliac Joints in Recent-Onset Axial Spondyloarthritis: 2-Year Data (EMBARK Trial and DESIR Cohort). The Journal of rheumatology 51 (5) (2024)
Maxime Dougados, Audrey Lardy-Cléaud, Emilie Desfleurs, Pascal Claudepierre, Philippe Goupille, Adeline Ruyssen-Witrand, Alain Saraux, Anne Tournadre, Daniel Wendling, Cédric Lukas
Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study. RMD open 10 (1) (2024)
Maxime Dougados, Audrey Lardy-Cléaud, Emilie Desfleurs, Pascal Claudepierre, Philippe Goupille, Adeline Ruyssen-Witrand, Alain Saraux, Anne Tournadre, Daniel Wendling, Cédric Lukas
Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study. RMD open 10 (1) (2024)
Léa Bastard, Pascal Claudepierre, Laetitia Penso, Emilie Sbidian, Laura Pina Vegas
Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (SNDS). RMD open 10 (1) (2024)
Anna Moltó, Chris Serrand, Sandrine Alonso, Francis Berenbaum, Pascal Claudepierre, Bernard G Combe, Laure Gossec, Adeline Ruyssen-Witrand, Alain Saraux, Daniel Wendling, Thierry Lequerre, Maxime Dougados
Diagnosis challenges in inception cohorts in axial spondyloarthritis: the case of the French national DESIR cohort. RMD open 10 (3) (2024)
Anna Moltó, Chris Serrand, Sandrine Alonso, Francis Berenbaum, Pascal Claudepierre, Bernard G Combe, Laure Gossec, Adeline Ruyssen-Witrand, Alain Saraux, Daniel Wendling, Thierry Lequerre, Maxime Dougados
Diagnosis challenges in inception cohorts in axial spondyloarthritis: the case of the French national DESIR cohort. RMD open 10 (3) (2024)
Laura Pina Vegas, Pascal Claudepierre
Trajectories of comorbidities in patients with psoriasis: a question to be answered. The British journal of dermatology 188 (3) (2023)
Laura Pina Vegas, Laetitia Penso, Emilie Sbidian, Pascal Claudepierre
Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French health insurance database (SNDS). RMD open 9 (4) (2023)
Laura Pina Vegas, Laetitia Penso, Emilie Sbidian, Pascal Claudepierre
Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French health insurance database (SNDS). RMD open 9 (4) (2023)
Maxime Dougados, Julien Lucas, Emilie Desfleurs, Pascal Claudepierre, Philippe Goupille, Adeline Ruyssen-Witrand, Alain Saraux, Anne Tournadre, Daniel Wendling, Cédric Lukas
Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA). RMD open 9 (1) (2023)
Laura Pina Vegas, Laetitia Penso, Emilie Sbidian, Pascal Claudepierre
Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French health insurance database (SNDS). RMD open 9 (4) (2023)
Laura Pina Vegas, Léa Hoisnard, Léa Bastard, Emilie Sbidian, Pascal Claudepierre
Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS). RMD open 8 (2) (2023)
Laura Pina Vegas, Pascal Claudepierre
Trajectories of comorbidities in patients with psoriasis: a question to be answered. The British journal of dermatology 188 (3) (2023)
Laura Pina Vegas, Laetitia Penso, Emilie Sbidian, Pascal Claudepierre
Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French health insurance database (SNDS). RMD open 9 (4) (2023)
Laura Pina Vegas, Léa Hoisnard, Léa Bastard, Emilie Sbidian, Pascal Claudepierre
Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS). RMD open 8 (2) (2023)
Maxime Dougados, Julien Lucas, Emilie Desfleurs, Pascal Claudepierre, Philippe Goupille, Adeline Ruyssen-Witrand, Alain Saraux, Anne Tournadre, Daniel Wendling, Cédric Lukas
Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA). RMD open 9 (1) (2023)
Maxime Dougados, Julien Lucas, Emilie Desfleurs, Pascal Claudepierre, Philippe Goupille, Adeline Ruyssen-Witrand, Alain Saraux, Anne Tournadre, Daniel Wendling, Cédric Lukas
Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA). RMD open 9 (1) (2023)
Joanna Kedra, Pascal Claudepierre, René-Marc Flipo, Marco Garrido-Cumbrera, Françoise Alliot-Launois, Emilie Desfleurs, Laurent Grange, Laure Gossec
Impact of Axial Spondyloarthritis on Quality of Life: Results From the European Map of Axial Spondyloarthritis (EMAS) Study in France. The Journal of rheumatology 49 (10) (2022)
Laura Pina Vegas, Pascal Claudepierre
Trajectories of comorbidities in patients with psoriasis: a question to be answered. The British journal of dermatology (2022)
Maxime Dougados, Julien Lucas, Emilie Desfleurs, Cédric Lukas, Alain Saraux, Anne Tournadre, Adeline Ruyssen-Witrand, Daniel Wendling, Philippe Goupille, Pascal Claudepierre
Impact of disease activity outcome measures reporting in the medical records of patients with axial spondyloarthritis on the retention rates of biological treatment: the example of secukinumab use in daily practice in France. RMD open 8 (1) (2022)
Catherine Beauvais, Bruno Pereira, Thao Pham, Christelle Sordet, Pascal Claudepierre, Francoise Fayet, Daniel Wendling, Félicie Costantino, Laurence Carton, Laurent Grange, Martin Soubrier, Nathalie Legoupil, Aleth Perdriger, Isabel Tavares, Emmanuelle Dernis, Laure Gossec, Malory Rodere
Development and Validation of a Self-Administered Questionnaire Measuring Essential Knowledge in Patients With Axial Spondyloarthritis. The Journal of rheumatology (2022)